Article

CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma

2021-04-03

Abstract excerpt

<title>Abstract</title> <p>In recent years, chimeric antigen receptor (CAR) T cell therapy has shown great promise in treating hematological malignancies. However, CAR T cell therapy currently has several limitations. Here we successfully developed a two-in-one approach to generate non-viral genome specific targeted CAR T cells through CRISPR/Cas9. Based on the optimized protocol, the feasibility was preliminaril...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bd5fa814-c4d0-52c2-ac84-be701eec066d
DOI: 10.21203/rs.3.rs-373651/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphomaDOI 10.21203/rs.3.rs-373651/v1Read

Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity Read

Strengthening the CAR-T Cell Therapeutic Application using CRISPR/Cas9 TechnologySemantic proximity Read

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphomaSemantic proximity Read

Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technologySemantic proximity Read

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapySemantic proximity Read

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapySemantic proximity Read

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene EditingSemantic proximity Read

Preferential disruption of HLA-A/B enhances allogeneic CAR-T cell expansion and antitumor capacity in B cell malignanciesSemantic proximity Read

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesSemantic proximity Read

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read

An <i>in vivo</i> CRISPR screen unveils top target genes to improve CAR-T cell efficacy in a solid tumor modelSemantic proximity Read